Literature DB >> 17207089

Performance of combined clinical mammography and needle biopsy: a nationwide study from Denmark.

Allan Jensen1, Fritz Rank, Uffe Dyreborg, Niels Severinsen, Susanne Nielsen, Elsebeth Lynge, Ilse Vejborg.   

Abstract

Clinical mammography and needle biopsy are key tools for non-operative assessment of breast lesions. We evaluated the performance of all combined tests undertaken in Denmark in 2000. Clinical mammography and needle biopsy data were collected and linked to final cancer outcome, to determine sensitivity, specificity, and predictive values of clinical mammography, needle biopsy, and combined test. In 2000, 6709 combined tests were performed in 36 mammography clinics in Denmark. The combined test was consistently more sensitive than any single test, increasing the proportion of women correctly identified with breast cancer by 9% compared with clinical mammography alone. For concordant combined tests (i.e. either both benign or both malignant), specificity and positive predictive value were 100%, sensitivity was 99.1%, and positive predictive value was 99.6%. Therefore, Danish patients with a malignant concordant combined test can proceed directly to definitive surgery without fear of a false-positive diagnosis, and Danish women with a concordant benign combined test can omit surgery without fear of a false-negative diagnosis. In discordant cases, our results showed that any of the two tests with a suspicious or malignant result indicated a high risk of cancer, and excisional diagnostic biopsy therefore still has an important role to play.

Entities:  

Mesh:

Year:  2006        PMID: 17207089     DOI: 10.1111/j.1600-0463.2006.apm_408.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  1 in total

1.  Performance of diagnostic mammography differs in the United States and Denmark.

Authors:  Allan Jensen; Berta M Geller; Charlotte C Gard; Diana L Miglioretti; Bonnie Yankaskas; Patricia A Carney; Robert D Rosenberg; Ilse Vejborg; Elsebeth Lynge
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.